Lundquist Institute researcher Dr. Eric Daar and research team find that HIV patients benefit from ingestible sensor technology for HIV treatment

Results published in The Lancet Ebiomedicine demonstrate the positive effect of an advanced ingestible sensor for HIV therapeutics

Ingestible Sensor Technology – Smart Pill

The study used a tiny edible sensor that is over-encapsulated with drugs. When ingested, it is detected by a patch with an integrated monitor and sensor worn by the patient. The monitor sends a Bluetooth signal to a mobile device, which in turn sends an encrypted message to a central server which records, in real time, that a dose of medication has just been taken.

Torrance, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) — LOS ANGELES (November 15, 2022) — Dr. Eric Daar, a researcher at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, is the co-principal investigator for the grant $4 million from the National Institute of Mental Health that supported research that found that HIV-positive patients whose drug regimens were monitored by an innovative ingestible sensor system were more adherent to antiretrovirals (ARVs) and, at in turn, had lower viral loads. The results – “Ingestible Sensor System for Measuring, Monitoring and Enhancing Adherence to Antiretroviral Therapy: An Open-label, Usual Care-controlled, Randomized Trial” – were published on November 11 in The Lancet Ebiomedicine.

The research team included researchers from UCLA, Nebraska Medical Center, Yale University and Harvard University. The team assessed the feasibility, acceptability, and sustainability of using the Proteus Digital Health Feedback (PDHF) information technology system, assessed its accuracy, and evaluated its effectiveness for monitoring and leveraging adherence. to medications. The published results constitute a significant advance in the measurement and monitoring of medication adherence in patients with HIV-AIDS and in the development of real-time interventions in a population that requires increased medical supervision.

“When patients first enrolled in our study, they had difficulty adhering to their medications regularly. During the study, they often expressed that the ingestible sensor technology system provided them with the additional feedback and support they needed to successfully control their HIV infection,” said Dr. Daar, Head of the division of HIV medicine at Harbor-UCLA Medical Center. and Professor of Medicine at the David Geffen School of Medicine at UCLA.

PDHF uses a tiny edible sensor that is over-encapsulated with drugs. When ingested, it is detected by a patch with an integrated monitor and sensor worn by the patient. The monitor sends a Bluetooth signal to a mobile device, which in turn sends an encrypted message to a central server which records, in real time, that a dose of medication has just been taken.

“After more than two decades of technology improvements, ingestible sensor technology is, to date, the most advanced and accurate computational method for measuring and monitoring adhesion behavior with wireless and online processes. real-time via a mobile device,” said Dr. Honghu Liu, co-principal investigator of the study and chair of the Section of Population and Public Health at UCLA School of Dentistry. “Our study provided particularly promising results for those who have significant difficulty adhering to antiretroviral medications.”

Media contact for the Lundquist Institute:

Max Benavidez, PhD, [email protected] 310-200-2682

Link to article: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964%2822%2900512-6/fulltext

Attachment

CONTACT: Max Benavidez The Lundquist Institute for Biomedical Innovation 310-200-2682 [email protected]

About Bradley J. Bridges

Check Also

Life expectancy 6.3 years shorter for black MSM living with HIV

WASHINGTON, DC – The life expectancy of HIV-infected non-Hispanic black men who have sex with …